Investor Sirenia Capital Management LP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Sirenia Capital Management LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2026-05-15 13G IMNM / Immunome, Inc. 6,895,000
2026-05-15 13G IBIO / iBio, Inc. 11,586,340
2026-05-15 13G EDSA / Edesa Biotech, Inc. 600,000
2026-05-15 13G DNTH / Dianthus Therapeutics, Inc. 2,798,122
2026-05-15 13G HELP / Cybin Inc. 3,677,966
2026-05-15 13G CRVS / Corvus Pharmaceuticals, Inc. 6,831,828
2026-05-15 13G ANAB / AnaptysBio, Inc. 1,920,402
2026-05-15 13G CCCC / C4 Therapeutics, Inc. 23,505,000
2026-05-15 13G ANRO / Alto Neuroscience, Inc. 2,591,587
2026-05-15 13G TNXP / Tonix Pharmaceuticals Holding Corp. 1,297,470
2026-05-15 13G XLO / Xilio Therapeutics, Inc. 1,142,862
2026-05-15 13G QTTB / Q32 Bio Inc. 2,057,308
2026-05-15 13G PTN / Palatin Technologies, Inc. 2,307,000
2026-05-15 13G OVID / Ovid Therapeutics Inc. 18,031,333
2026-05-15 13G OKYO / OKYO Pharma Limited 4,054,054
2026-05-15 13G KOD / Kodiak Sciences Inc. 3,495,000